Free Republic

Subcutaneous injection of the immunotherapy nivolumab (brand name Opdivo) is noninferior to intravenous delivery and dramatically reduces treatment time in patients with renal cell carcinoma, as seen in the results of a large phase 3 clinical trial reported today. "The burden of treatment felt by cancer patients is tremendous. If nivolumab can be given as a subcutaneous injection instead of an intravenous infusion, their treatment experience will be significantly improved," says Dr. George. "Instead of one hour in an infusion chair, they will get the injection done in five minutes." The clinical trial began in May 2021, randomizing 495 patients...

Doctors using a treatment called nivolumab on a lung cancer patient with Aids noticed a “drastic and persistent” decrease in infected white blood cells A new cancer drug could “cure” HIV, a revolutionary study suggests. Doctors using a treatment called nivolumab on a lung cancer patient with Aids noticed a “drastic and persistent” decrease in infected white blood cells. The findings have raised hopes that drugs could one day eradicate the HIV virus, which attacks the immune system and cur­­rently has no cure. At present, those infected must take anti-HIV drugs for the rest of their lives to stop the...